Nalbuphine ER

Technology

Last mentioned: Mar 18, 2026

Timeline

  1. Q4 Earnings Call

    Management details strategic advances and future clinical roadmap.

  2. Data Readout

    Anticipated Phase 2b/3 data for Haduvio in chronic cough indications.

  3. Fiscal Year End

    Trevi concludes 2025 with key clinical milestones met for IPF chronic cough.

  4. Q4 Strategic Pivot

    Trevi refocuses resources on Haduvio's late-stage respiratory trials.

Stories mentioning Nalbuphine ER 1

market-trends Neutral

Trevi Therapeutics Advances Chronic Cough Pipeline Amid Q4 Strategic Pivot

Trevi Therapeutics reported significant strategic progress in its Q4 2025 earnings, focusing on the clinical development of Haduvio for chronic cough in IPF. While the company achieves key R&D milestones, the broader biotech sector continues to navigate a complex financial landscape characterized by high capital costs and strategic realignments.

2 sources